Summary
Pfizer Inc. (PFE) has announced the completion of a substantial public offering totaling $30 billion in aggregate principal amount across eight different note issuances, ranging from 2025 to 2063 maturities and carrying interest rates between 4.450% and 5.340%. These notes are fully and unconditionally guaranteed by Pfizer Inc. on a senior unsecured basis. The primary purpose of this significant debt issuance is to finance a portion of the consideration for Pfizer's proposed acquisition of Seagen Inc. An important detail for investors is the conditional nature of the debt utilization. If the Seagen acquisition does not close by a specified date (or if Pfizer decides not to pursue it), a Special Mandatory Redemption will be triggered for most of the notes (excluding the 2033 and 2053 Notes). In such an event, these redeemed notes will be repurchased at 101% of their principal amount plus accrued interest. The proceeds from the 2033 and 2053 Notes, however, would be available for general corporate purposes, potentially including existing debt obligations.
Key Highlights
- 1Pfizer Inc. completed a $30 billion debt offering across multiple tranches and maturities.
- 2The debt is fully and unconditionally guaranteed by Pfizer Inc.
- 3The offering is primarily intended to finance Pfizer's proposed acquisition of Seagen Inc.
- 4A Special Mandatory Redemption clause exists for most notes if the Seagen acquisition does not close.
- 5The Special Mandatory Redemption price is set at 101% of the principal amount plus accrued interest.
- 6The 2033 and 2053 Notes have different redemption provisions and their proceeds may be used for general corporate purposes if redeemed.
- 7The offering was registered under Pfizer's shelf registration statement on Form S-3, with an amendment filed on May 15, 2023.